植物制剂(沙巴棕)、坦索罗辛、非那雄胺三者治疗BPH继发下尿路症状的患者性功能方面的疗效对比精选.pdfVIP

European Urology European Urology 48 (2005) 269–276 BPH/Prostatic Diseases Evaluation of Male Sexual Function in Patients with Lower UrinaryTract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH) Treated with a Phytotherapeutic Agent (Permixon1), Tamsulosin or Finasteride a,* b c a Alexandre R. Zlotta , Pierre Teillac , Jean Pierre Raynaud , Claude C. Schulman aDepartment of Urology, Erasme Hospital, University Clinics of Brussels, 808 route de Lennik, B-1070 Brussels, Belgium bDepartment of Urology, St-Louis Hospital, Paris, France c University Pierre and Marie Curie, Paris, France Accepted 24 March 2005 Available online 18 April 2005 Abstract Objectives: Sexual function is one of the aspects in the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) that has gained increasing attention. We compared the influence on men’s sexuality of Permixon, a lipido-sterolic extract of Serenoa Repens, with Tamsulosin and Finasteride using a specific validated questionnaire exploring patient’s sexual functions. Methods: A database was created comprising patients from 3 main double-blind, randomized studies - Permixon vs. Finasteride, Permixon vs. Tamsulosin and Permixon 160 mg vs. 320 mg including a total of 2511 patients. Three hundred fifty four were on Tamsulosin, 545 on Finasteride and 1612 patients on Permixon. LUTS were assessed using the I-PSS questionnaire. Peak flow rates and prostate volume were recorded. The MSF-4 questionnaire, including 4 items that explore the patient’s interest in sex, quality of erection, achievement of orgasm and ejaculation, was used across the studies. This questionnaire was demonstrated as highly reproducible and both psychometrically and clinically valid